A Comparison of Preferences for the Benefits and Risks of Statins Among Korean Physicians and Patients Using a Discrete-Choice Experiment

Abstract

A 7 1 9 -A 8 1 3 A757 hospitalization from heart failure, and cerebrovascular events. Logistic regression of potential-confounders at PD initiation was performed to determine propensity scores (PS), probability of prescribing colchicine. PS and covariates were controlled in multivariable Cox hazard regression models to investigate association of colchicine and CV events. Results: Of 366 subjects, 57 (15.6%) received colchicine, 75 (20.5%) had history of CV events. Follow-up was shorter in the non-users, 19.1 months median (range 3.05-70.0) vs. 26.5 (3.2-71.3). CV events occurred in 7 (12.3%) in the users and 82 (26.5%) in the non-users. Both groups did not differ on entry Charlson co-morbidity index, estimated glomerular filtration rate, serum uric acid levels. Adjusted hazard ratio (HR) of CV events was lower in colchicine users for primary CV events (adjHR 0.28; 95% CI, 0.09-0.90, p= 0.033), and secondary CV events (adjHR 0.29; 95% CI, 0.08-0.99, p= 0.049). Moreover, colchicine users had fewer CV mortality and all-causes mortality, although statistical significance was not found. ConClusions: Colchicine appeared to associate with reducing risk of primary and secondary CV events, and demonstrated trends toward lower CV mortality and all-causes mortality in PD patients.objeCtives: To investigate the management of hypertension in adult Malaysian population suffering from chronic kidney disease stage (CKD) stage 3-5. Methods: A retrospective, cross-sectional study was conducted on 300 patients with CKD stage 3 (n = 98), 4 (n = 76) and 5 (n = 126) in CKD Results: The mean age of all patients was 58.86 ± 13.47 years and there was preponderance of male subjects (69%). The prevalence of hypertension was 91.3%; almost universal among the sufferers of stage 3, 4 and 5 of CKD (87.8%, 94.7% and 92.1%, respectively). In CKD stage 5, mean systolic blood pressure was considerably higher than in stage 4 and 3 (p = 0.009).The percentage of patients with systolic BP < 130 mm Hg and diastolic BP < 80 mm Hg was 30.3% and 49.0%, respectively. Only 24.3% of the total patients had BP < 130/80 mm Hg despite usingmultiple antihypertensive medications. The proportion of patients consuming antihypertensive drugs was as: angiotensin-converting enzyme inhibitors (ACE-Is) (25%), angiotensin receptor blockers (ARBs) (14.3%),combined ACE-Is and ARBs (2.7%), calcium channel blockers (66.3%), β -blockers (40.7%), diuretics (60%) and α -blockers (14.3%). There was significantly lower percentage of patients on ACE-Is and ARBs in stage 5 than in stage 4 and 3 CKD patients. Proteinuria was present in 71.7% of the patients and there was significant difference proteinuria between stage 3, 4 and 5 (55.1 vs 59.2 vs 92.1, p = 0.000). ConClusions: Underutilization of some classes of anti-hypertensive medications is apparent.Higher percentage of proteinuria in CKD stage 5 patients may be attributed to the underuse of ACE-Is and ARBs in stage 5.The study further indicated the need of employinginstructive efforts to get valuable outcomes of antihypertensive...